Global Markets Direct’s, ‘Septic Shock - Pipeline Review, H1 2016’, provides an overview of the Septic Shock pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Septic Shock, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Septic Shock and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
- The report provides a snapshot of the global therapeutic landscape of Septic Shock - The report reviews pipeline therapeutics for Septic Shock by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Septic Shock therapeutics and enlists all their major and minor projects - The report assesses Septic Shock therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Septic Shock
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Septic Shock - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Septic Shock pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Our reports have been used by over 10K customers, including:
Histone Deacetylase 1 - Pipeline Review, H2 2020 Summary Histone Deacetylase 1 (HDAC1 or EC 126.96.36.199) pipeline Target constitutes close to 38 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The latest report Histone Deacetylase...
Cathepsin L1 - Pipeline Review, H2 2020 Summary Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 188.8.131.52) - Cathepsin L, a lysosomal endopeptidase is a member of the papain-like family of cysteine proteinases. Cathepsin L plays a major role in antigen processing, tumor invasion...
Exportin 1 - Pipeline Review, H2 2020 Summary Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) pipeline Target constitutes close to 8 molecules. The latest report Exportin 1 - Pipeline Review, H2 2020, outlays comprehensive information on the Exportin 1 (Chromosome Region Maintenance...
Growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), and the growing prevalence of respiratory diseases and alpha-1-antitrypsin deficiency (AATD) is expected to drive the overall growth of the plasma fractionation market. The global plasma fractionation...
Histone Deacetylase 2 - Pipeline Review, H2 2020 Summary Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 184.108.40.206) - Histone deacetylase 2 is an enzyme encoded by the HDAC2 gene. It plays an important role in transcriptional regulation, cell...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.